These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37968873)

  • 1. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
    Schjesvold FH; Ludwig H; Mateos MV; Larocca A; Abdulhaq H; Norin S; Thuresson M; Bakker NA; Richardson PG; Sonneveld P
    Eur J Haematol; 2024 Mar; 112(3):402-411. PubMed ID: 37968873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
    Schjesvold FH; Dimopoulos MA; Delimpasi S; Robak P; Coriu D; Legiec W; Pour L; Špička I; Masszi T; Doronin V; Minarik J; Salogub G; Alekseeva Y; Lazzaro A; Maisnar V; Mikala G; Rosiñol L; Liberati AM; Symeonidis A; Moody V; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Hájek R; Mateos MV; Richardson PG; Sonneveld P;
    Lancet Haematol; 2022 Feb; 9(2):e98-e110. PubMed ID: 35032434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
    Sonneveld P; Richardson PG; Ludwig H; Dimopoulos MA; Schjesvold FH; Hájek R; Abdulhaq H; Thuresson M; Norin S; Bakker NA; Mateos MV
    Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):687-696. PubMed ID: 37355418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
    Pour L; Szarejko M; Bila J; Schjesvold FH; Spicka I; Maisnar V; Jurczyszyn A; Grudeva-Popova Z; Hájek R; Usenko G; Thuresson M; Norin S; Jarefors S; Bakker NA; Richardson PG; Mateos MV
    Haematologica; 2024 Mar; 109(3):895-905. PubMed ID: 37646660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
    Richardson PG; Oriol A; Larocca A; Bladé J; Cavo M; Rodriguez-Otero P; Leleu X; Nadeem O; Hiemenz JW; Hassoun H; Touzeau C; Alegre A; Paner A; Maisel C; Mazumder A; Raptis A; Moreb JS; Anderson KC; Laubach JP; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;
    J Clin Oncol; 2021 Mar; 39(7):757-767. PubMed ID: 33296242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
    Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
    Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
    Schjesvold F; Robak P; Pour L; Aschan J; Sonneveld P
    Future Oncol; 2020 Apr; 16(11):631-641. PubMed ID: 32141766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
    Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
    Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
    Bringhen S; Voorhees PM; Plesner T; Mellqvist UH; Reeves B; Sonneveld P; Byrne C; Nordström E; Harmenberg J; Obermüller J; Richardson PG
    Br J Haematol; 2021 Jun; 193(6):1105-1109. PubMed ID: 33403663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
    Ocio EM; Efebera YA; Hájek R; Straub J; Maisnar V; Eveillard JR; Karlin L; Mateos MV; Oriol A; Ribrag V; Richardson PG; Norin S; Obermüller J; Bakker NA; Pour L
    Haematologica; 2024 Mar; 109(3):867-876. PubMed ID: 37646657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melflufen for the treatment of multiple myeloma.
    Ocio EM; Nadeem O; Schjesvold F; Gay F; Touzeau C; Dimopoulos MA; Richardson PG; Mateos MV
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):371-382. PubMed ID: 35723075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
    Jessee JK
    Ann Pharmacother; 2022 Aug; 56(8):951-957. PubMed ID: 34963319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melflufen for relapsed and refractory multiple myeloma.
    Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1069-1078. PubMed ID: 32924646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma.
    Huledal G; Ruiz-Garcia A; Kawakatsu S; Wang X; Sjöberg P; Gullbo J; Pekar D; Norin S; Jerling M
    J Clin Pharmacol; 2024 Feb; 64(2):240-252. PubMed ID: 37752623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melphalan flufenamide for relapsed/refractory multiple myeloma.
    Nadeem O; Mateos MV; Efebera YA; Paner A; Larocca A; Rodríguez-Otero P; Leleu X; Richardson PG
    Drugs Today (Barc); 2022 Aug; 58(8):407-423. PubMed ID: 35983927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma.
    Pour L; Micheva I; Usenko G; Mikala G; Masszi T; Simeonova K; Thuresson M; Huledal G; Norin S; Bakker NA; Minarik J
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e267-e275.e2. PubMed ID: 38490927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
    Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
    Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
    Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
    Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo activity of melflufen (J1)in lymphoma.
    Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
    BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.